Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Fineline Cube Jul 8, 2026
Company Drug

CSPC’s SYS 6043 Receives FDA Approval for Clinical Trials

Fineline Cube Jan 17, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its in-house developed SYS 6043...

Company Drug

Innovent’s Limertinib Wins NMPA Approval for NSCLC Treatment

Fineline Cube Jan 17, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that it has received New Drug Application...

Company

ConjuStar Completes $15 Million Pre-A+ Financing Round

Fineline Cube Jan 17, 2025

ConjuStar, a clinical-stage biotechnology company based in Tianjin, China, has announced the completion of a...

Company Deals

Bio-Thera Solutions Licenses BAT2206 to World Medicine for Turkey

Fineline Cube Jan 16, 2025

On January 16, Bio-Thera Solutions Ltd (SHA: 688177), a science – driven innovative global biopharmaceutical...

Company Deals

GE Healthcare and Sutter Health Form $1B Care Alliance

Fineline Cube Jan 16, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has formed...

Company Drug

HutchMed’s Orpathys Approved for Expanded NSCLC Indication in China

Fineline Cube Jan 16, 2025

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the National Medical Products Administration...

Company Drug

Innovent’s IBI343 Receives Breakthrough Therapy Designation for Pancreatic Cancer

Fineline Cube Jan 16, 2025

China-based biopharma Innovent Biologics, Inc. (HKG: 1801) has announced receiving another Breakthrough Therapy Designation (BTD)...

Company Drug

Wepon Medical’s WP107 Receives FDA Approval for gMG Clinical Trial

Fineline Cube Jan 16, 2025

China-based Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced receiving clinical trial approval...

Company Drug

Fosun Pharma Initiates Phase II Study for Glomerular Disease Treatment

Fineline Cube Jan 16, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...

Company Drug

Hengrui’s SHR-9839 Receives NMPA Clearance for Advanced Tumors

Fineline Cube Jan 16, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical clearance from the...

Legal / IP

Chipscreen’s Epidaza Patent Faces Invalidation Request Review

Fineline Cube Jan 16, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request...

Company Deals

Biogen Proposes to Acquire Sage Therapeutics for $469M

Fineline Cube Jan 15, 2025

US-based Sage Therapeutics, Inc. (NASDAQ: SAGE) has announced that it received an unsolicited, nonbinding proposal...

Company Deals Medical Device

Medtronic Secures Exclusive Distribution Rights for Contego’s Neuroguard and Excipio

Fineline Cube Jan 15, 2025

US-Irish firm Medtronic (NYSE: MDT) has entered into an exclusive distribution agreement with Contego Medical,...

Company Deals

Eli Lilly to Acquire Scorpion Therapeutics’ STX-478 for $2.5B

Fineline Cube Jan 15, 2025

US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from...

Company Deals

Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6B

Fineline Cube Jan 15, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) is set to acquire all outstanding shares of...

Company Deals

GSK Acquires IDRx for $1B to Boost GIST Treatment Pipeline

Fineline Cube Jan 15, 2025

UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has entered into an agreement with US-based biopharma IDRx, Inc....

Company Deals

Autobio Diagnostics Partners with Boditech Med for Korean IVD Market

Fineline Cube Jan 15, 2025

China-based Autobio Diagnostics Co., Ltd (SHA: 603658) has announced a strategic partnership with South Korea-headquartered...

Company Deals

Henlius and Abbott Sign License Agreement for Biosimilars and Biologic Drug

Fineline Cube Jan 15, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced a strategic license agreement with Abbott...

Company Drug

Chongqing Genrix’s Silevimig NDA Accepted for Rabies Immunization Review

Fineline Cube Jan 15, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) has announced that a New Drug...

Legal / IP

Novartis to Defend Entresto Patent After CAFC Ruling

Fineline Cube Jan 14, 2025

Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for...

Posts pagination

1 … 252 253 254 … 692

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
  • AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
  • OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model
  • Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus
  • Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Others

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

Others

OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model

Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.